FDA clears PhotoMedex' laser for leukoderma:
This article was originally published in Clinica
Executive Summary
PhotoMedex has received US FDA clearance to expand the use of its XTRAC laser system to the treatment of leukoderma, the loss of skin pigmentation often a result of injury to the skin caused by trauma, surgery, laser therapy and burns. The device stimulates melanocyte migration and proliferation by the release of cytokines and inflammatory mediators in the skin, which lead to re-pigmentation, says the Radnor, Pennsylvania firm. The laser is already cleared for treating psoriasis, vitiligo and eczema.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.